Back to Trial

Oracle Runs

Oracle findings and outcome history for An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (NCT03601078).

Runs
2
Findings
2
Latest Run
Apr 3, 2026, 4:02 PM
Resolution Evidence
Outcome
YES
Status
Resolved
Settlement Date
4/3/26 UTC
Executive Summary

NCT03601078 is the Phase 2 multi-cohort KarMMa-2 trial. Public readouts tied to this exact trial have been explicitly framed as positive: BMS said cohorts 2a/2c showed durable responses and predictable safety, and later cohort 2b reporting described a favorable benefit-risk profile with frequent, deep, durable responses. No cited trial-specific public source frames KarMMa-2 negatively.

Sources
ClinicalTrialsclinicaltrials.gov
Study Details | NCT03601078 | An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

ClinicalTrials.gov identifies NCT03601078 as KarMMa-2, a Phase 2, multicohort study of bb2121/ide-cel in relapsed/refractory and high-risk multiple myeloma.

View source
Sponsornews.bms.com12/12/22
Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022

For KarMMa-2, BMS said cohorts 2a/2c showed durable responses and predictable safety; it further said Abecma demonstrated complete and durable responses in a significant proportion of patients.

View source
Web Searchmultiplemyelomahub.com7/5/24
KarMMA-2 Cohort 2B: Ide-cel in early relapse clinical high-risk MM

This trial-specific summary says a single ide-cel infusion in KarMMa-2 cohort 2b had a favorable benefit-risk profile with frequent, deep, durable responses and manageable safety.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

YESAccepted79% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

NCT03601078 is the Phase 2 multi-cohort KarMMa-2 trial. Public readouts tied to this exact trial have been explicitly framed as positive: BMS said cohorts 2a/2c showed durable responses and predictable safety, and later cohort 2b reporting described a favorable benefit-risk profile with frequent, deep, durable responses. No cited trial-specific public source frames KarMMa-2 negatively.

Found Apr 3, 2026, 4:02 PMOutcome date Dec 12, 2022, 12:00 AMReviewed Apr 3, 2026, 5:19 PM
ClinicalTrialsclinicaltrials.gov
Study Details | NCT03601078 | An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
ClinicalTrials.gov identifies NCT03601078 as KarMMa-2, a Phase 2, multicohort study of bb2121/ide-cel in relapsed/refractory and high-risk multiple myeloma.
Sponsornews.bms.comDec 12, 2022, 12:00 AM
Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022
For KarMMa-2, BMS said cohorts 2a/2c showed durable responses and predictable safety; it further said Abecma demonstrated complete and durable responses in a significant proportion of patients.
Web Searchmultiplemyelomahub.comJul 5, 2024, 12:00 AM
KarMMA-2 Cohort 2B: Ide-cel in early relapse clinical high-risk MM
This trial-specific summary says a single ide-cel infusion in KarMMa-2 cohort 2b had a favorable benefit-risk profile with frequent, deep, durable responses and manageable safety.
NO_DECISIONDismissed85% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No clear overall trial-level public readout was found for NCT03601078. Public evidence found was cohort-specific and favorable (eg, KarMMa-2 cohort 2c and 2b), while BMS still described KarMMa-2 as part of its ongoing/planned development program rather than reporting a definitive whole-trial topline outcome.

Found Apr 1, 2026, 6:35 PMReviewed Apr 1, 2026, 6:36 PM
Sponsornews.bms.com
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
BMS said Abecma’s development program includes ongoing and planned studies, specifically naming KarMMa-2, KarMMa-3, and KarMMa-9.
Sponsornews.bms.com
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for RRMM
This sponsor release cites extended follow-up from KarMMa-2 cohort 2c only: deep/durable responses, 77.4% CR, ORR 87.1%, and no new safety signals.
Web Searchmultiplemyelomahub.comJul 5, 2024, 12:00 AM
KarMMA-2 Cohort 2B: Ide-cel in early relapse clinical high-risk MM
This report is also cohort-specific, calling a single ide-cel infusion favorable benefit-risk with frequent, deep, durable responses and manageable safety in cohort 2b.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle ReviewApr 3, 2026, 5:19 PM

Will the results be positive?

PendingtoYEScurrentYES
GPT-5.4 (OpenAI)79% confidenceReviewed Apr 3, 2026, 5:19 PM

NCT03601078 is the Phase 2 multi-cohort KarMMa-2 trial. Public readouts tied to this exact trial have been explicitly framed as positive: BMS said cohorts 2a/2c showed durable responses and predictable safety, and later cohort 2b reporting described a favorable benefit-risk profile with frequent, deep, durable responses. No cited trial-specific public source frames KarMMa-2 negatively.